---
title: "AstraZeneca CEO Hails NHS Drug Deal, Keeps £200m Cambridge Project on Hold"
summary: "AstraZeneca CEO Pascal Soriot welcomed the UK‑US drug‑pricing agreement as a good step, but said it won’t lift the pause on a £200 m research centre in Cambridge. He stressed the US is still the company’s biggest market and that more practical steps are needed before the project can start. The drugmaker is still forecasting steady growth and has recently seen its share price rise."
section: "Business"
category: "Corporate Business News"
imageUrl: "https://media.guim.co.uk/eaa96eba60bd83e1df2c89f49d9f258a1533f1c1/0_227_5353_4282/500.jpg"
publishedAt: "2026-02-10T12:26:15Z"
guardianId: "business/2026/feb/10/astrazeneca-ceo-pascal-soriot-nhs-drug-price-deal-uk-investment-cambridge"
---

AstraZeneca CEO Pascal Soriot welcomed the UK‑US drug‑pricing agreement as a good step, but said it won’t lift the pause on a £200 m research centre in Cambridge. He stressed the US is still the company’s biggest market and that more practical steps are needed before the project can start. The drugmaker is still forecasting steady growth and has recently seen its share price rise.
